Associations between maternal serum free beta human chorionic gonadotropin (β-hCG) levels and adverse pregnancy outcomes.

Item

http://www.wikidata.org/entity/Q41363097

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Associations between maternal ...... nd adverse pregnancy outcomes.

@en

type

Item

label

Associations between maternal ...... nd adverse pregnancy outcomes.

@en

prefLabel

Associations between maternal ...... nd adverse pregnancy outcomes.

@en

P1476

Associations between maternal ...... nd adverse pregnancy outcomes.

@en

P2093

C Wanapirak

http://www.w3.org/2001/XMLSchema#string

K Srisupundit

http://www.w3.org/2001/XMLSchema#string

P Sirikunalai

http://www.w3.org/2001/XMLSchema#string

S Sirichotiyakul

http://www.w3.org/2001/XMLSchema#string

P2860

Obstetrical complications associated with abnormal maternal serum markers analytes.

First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.

Mid-trimester maternal serum HCG and alpha fetal protein levels: clinical significance and prediction of adverse pregnancy outcome

First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes.

Isolated low second-trimester maternal serum beta-human chorionic gonadotropin is not associated with adverse pregnancy outcome.

Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes.

Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.

Quad screen as a predictor of adverse pregnancy outcome.

First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).

Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth.

P304

178-182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/01443615.2015.1036400

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Theera Tongsong

Suchaya Luewan

Fuanglada Tongprasert

K Traisrisilp

P577

2015-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26368010

http://www.w3.org/2001/XMLSchema#string